WallStSmart
IMMX

Immix Biopharma Inc

NASDAQ: IMMX · HEALTHCARE · BIOTECHNOLOGY

$10.10
+0.90% today

Updated 2026-06-03

Market cap
$620.78M
P/E ratio
P/S ratio
EPS (TTM)
$-0.92
Dividend yield
52W range
$2 – $12
Volume
1.3M

Immix Biopharma Inc (IMMX) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item2019202020212022202320242025
Total assets$942944.00$539597.00$18.19M$14.91M$19.93M$22.95M$104.84M
Cash & equivalents$734014.00$391086.00$17.64M$13.44M$17.51M$17.68M$93.93M
Current assets$933262.00$532236.00$18.19M$14.90M$19.79M$20.20M$101.24M
Total liabilities$4.59M$5.27M$202039.00$1.75M$3.72M$9.70M$11.04M
Current liabilities$4.59M$5.27M$202039.00$1.27M$3.72M$8.69M$10.11M
Long-term debt
Shareholder equity$-3.65M$-4.73M$17.99M$13.16M$16.41M$13.25M$93.80M
Retained earnings$-4.22M$-5.37M$-29.76M$-37.99M$-53.41M$-75.02M$-104.46M
Accounts receivable$175748.00$127436.00$25722.00$255705.00$1.17M$1.97M
Inventory
Goodwill

Frequently asked questions

How much free cash flow does IMMX generate?

IMMX produced $-24.66M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is IMMX's balance sheet healthy?

IMMX holds $93.93M in cash and equivalents against — in long-term debt, on $93.80M of shareholder equity. That debt is best read against the cash flow the business throws off each year.